Viking Therapeutics, Inc., a biopharmaceutical company operating within the health care sector, has recently achieved a significant milestone in its clinical research endeavors. The company, which specializes in developing therapeutics for metabolic and endocrine disorders, announced the completion of patient enrollment for its Phase 3 VANQUISH-2 study. This study focuses on the dual GLP-1/GIP agonist, VK2735, and is designed to assess its efficacy in treating adults with type 2 diabetes and obesity or overweight conditions.
The VANQUISH-2 trial is a multicentre, randomized, double-blind, placebo-controlled study that will span 78 weeks. It involves approximately 1,000 participants who will receive weekly subcutaneous injections. The study will compare four dose groups: 7.5 mg, 12.5 mg, 17.5 mg, and a placebo group. The primary endpoint of the trial is the percent change in body weight at week 78. Following the main study period, a 52-week extension will be offered to participants, allowing them to continue treatment.
In addition to the VANQUISH-2 study, Viking Therapeutics is concurrently advancing its Phase 3 VANQUISH-1 program and a Phase 1 maintenance-dose study. The latter is anticipated to report results in the third quarter of 2026. These studies build on the promising outcomes of the company’s earlier Phase 2 VENTURE trial, which demonstrated significant weight-loss benefits and a favorable safety profile, thereby supporting the progression to the current Phase 3 milestones.
Viking Therapeutics, Inc. is headquartered in La Jolla, United States, and is listed on the Nasdaq stock exchange. The company’s market capitalization stands at approximately $3.96 billion, with a close price of $32.52 as of March 26, 2026. Despite a negative price-to-earnings ratio of -10.76, the company’s strategic focus on innovative therapeutic solutions for metabolic and endocrine disorders positions it as a notable entity within the biotechnology industry. Further information about Viking Therapeutics can be accessed through their website at www.vikingtherapeutics.com .
